Celsis International PLC
19 March 2003
CELSIS INTERNATIONAL PLC
Pre Close Trading Update
Celsis International plc ('Celsis'), a world leading cGMP laboratory services
and rapid microbial testing company, whose diagnostic systems detect and measure
contamination, for the pharmaceutical, personal care, dairy and beverage
industries, will announce preliminary results for the year ending 31st March
2003 on 22nd May 2003.
Jay LeCoque, CEO, making the following comment on trading in the second half of
the year, said:
'Despite the current uncertainties in world markets, we have continued our
robust trading into the second half of our financial year. Our restructured
business units have solidified our core operations, enabling us to build upon
these revitalized platforms to secure new growth across all market segments.
'We are pleased with the progress being made despite the difficult worldwide
economic environment and I am happy to report Group profits in line with market
expectations'
19th March 2003
Enquiries:
Celsis International plc Tel: 01638 600 151
Jay LeCoque, Chief Executive Officer
Jenny Parsons, Corporate Communications
College Hill Tel: 020 7457 2020
Nicholas Nelson
Notes to editors:
Celsis International plc (www.celsis.com) is a world leader in the development
and supply of rapid diagnostic and monitoring systems to detect and measure
microbial contamination in finished products bound for consumers. It has
successfully developed tests for use in the pharmaceutical, cosmetic and
toiletries, food and beverage industries and is associated with some of the
best-known high street brands in these consumer areas.
These tests are based upon the years of research in enzyme technology that
employ numerous methods for the rapid detection of microbial contamination. The
result is that microbial testing times are reduced from around five days to a
little over one day, thus lending significant cost advantages to Celsis'
customers.
Celsis International plc also has a leading cGMP laboratory services, supporting
the R&D and manufacturing based testing needs of the pharmaceutical,
biotechnology and personal care industries. This business unit currently
operates primarily in the United States.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.